and indispensable function in hematopoietic and vessel development during embryogenesis. [10] [11] [12] [13] [14] [15] [16] [17] Despite the importance of ETV2 in early embryonic hematopoietic and vascular development, Etv2 inactivation after hematopoietic and endothelial cell specification using Tie2-Cre leads to normal development, 18 indicating that ETV2 has a transient role in the specification of hematopoietic and endothelial lineages. However, potential functions of ETV2 in adult vascular homeostasis and pathophysiological angiogenesis have not yet been addressed. To directly investigate a role for ETV2 in postnatal vascular regeneration, we generated and characterized conditional knockout (CKO) mice lacking endothelial Etv2 by targeting the floxed allele of Etv2 with Tie2-Cre [19] [20] [21] or VECadherin-Cre. 22 Consistent with the observations of Kataoka et al, 18 we found that endothelial Etv2 was not required for embryonic development or maintenance of the adult vasculature; however, mice lacking endothelial Etv2 exhibited significantly impaired new vessel formation in response to tissue injuries including laser-induced eye injury, 23 wounding, 24 or hindlimb ischemic injury, 25, 26 which are models for age-related macular degeneration, wound healing, and peripheral arterial disease, respectively. Moreover, lentiviral delivery of Etv2 into ischemic hindlimbs led to improved recovery of blood perfusion, augmented angiogenic gene expression, and enhanced vascular regeneration. We also identify the FLK1 pathway as a major downstream effector of ETV2 in injury-induced neovascularization. These results highlight a requisite postnatal function of ETV2 in injuryinduced neovascularization.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Etv2 Is Upregulated in Response to Injury and Required for Neovascularization
To investigate the role of Etv2 after the hematopoietic and endothelial cell lineage specification, we generated Tie2-Cre; Etv2 (Etv2 f/f or Etv2 f/-) CKO mice. Consistent with the previous report, 18 Tie2-Cre; Etv2 CKO mice were born at near expected Mendelian ratios and were viable, healthy, and fertile. Successful deletion of the floxed Etv2 allele was verified in purified lung endothelial cells (CD31 In adult tissue, Etv2 expression is extremely low or undetectable, even in isolated endothelial cells 27 ( Figure III in the online-only Data Supplement). However, after hindlimb ischemic injury endothelial Etv2 expression was readily upregulated (Figure 2A ; Figure III in the online-only Data Supplement), suggesting its role in neoangiogenesis. To directly determine if Etv2 was required for injury-induced vascular regeneration, we subjected Tie2-Cre; Etv2 CKO mice to hindlimb ischemia 25, 26, 28 and assessed their vascular regeneration ability. As expected, Etv2 expression was almost undetectable in the endothelial cells from Tie2-Cre; Etv2 CKO mice after injury ( Figure 2B ). Laser Doppler Perfusion Image analysis revealed significantly impaired blood perfusion in Tie2-Cre; Etv2 CKO hindlimbs, compared with control mice ( Figure 2C and 2D). Capillary density as determined by CD31 (PECAM1) or VECADHERIN staining was lower in the CKO mice after injury ( Figure 2E and 2F). The impaired blood perfusion observed in Tie2-Cre; Etv2 CKO mice was because of Etv2 deficiency as demonstrated by the rescue experiment with lentiviral Etv2 injection ( Figure IV in the online-only Data Supplement). To confirm that endothelial Etv2 is responsible for the results of Tie2-Cre; Etv2 CKO mice, we additionally generated VECadherin-Cre; Etv2 (Etv2 f/f or Etv2 f/− ) CKO mice to specifically delete Etv2 in endothelial cells. 22 VECadherin-Cre; Etv2 CKO mice were also obtained at expected Mendelian ratios and were healthy. Importantly, VECadherin-Cre; Etv2 CKO mice displayed similar angiogenesis defects in hindlimb ischemic injury response as observed in Tie2-Cre; Etv2 CKO mice ( Figure 2G-2J) . It is well appreciated that both hematopoietic and endothelial cells are required for optimal recovery from hindlimb ischemic injury. 29, 30 Thus, we generated and performed hindlimb ischemia studies using Vav-Cre; Etv2 CKO mice (hematopoietic Etv2 deletion) 31, 32 to determine hematopoietic Etv2 contribution to vascular regeneration. As shown in Figure V in the online-only Data Supplement, Vav-Cre; Etv2 CKO mice did not show deficiency in blood perfusion recovery at early time points, days 7 and 14. Only at a later time, day 21, blood perfusion was decreased, compared with controls. These data suggest a key contribution of endothelial Etv2 in ischemiainduced angiogenesis.
In addition to reduced vessel repair ability after hindlimb ischemic injury, Tie2-Cre; Etv2 CKO mice also displayed reduced vascular regeneration ability in a mouse model of choroidal neovascularization, the major cause of blindness of age-related macular degeneration. 23 Figure  VIA -VIC in the online-only Data Supplement). Etv2 expression was observed at day 4 after the injection, although it was no longer detected after about a month ( Figure VID and VIE in the online-only Data Supplement). Although control Venus lentivirus injection had no effect on limb perfusion recovery, Etv2 lentivirus injection protected mice considerably from limb loss or foot necrosis when examined 28 days later ( Figure 4A and 4B). Consistently, Laser Doppler Perfusion Image analysis showed enhanced blood perfusion recovery in mice injected with Etv2 lentivirus, compared with mice injected with control Venus lentivirus ( Figure 4C and 4D) . Similar results were also obtained in C57BL/6J mice, which have strong recovery ability of blood perfusion after ischemic injury ( Figure Figure 5C ). We additionally found vessels that were 50 to 100 µm in diameter and augmented numbers of smooth muscle α-ACTIN + BrdU + cells in Etv2 lentivirus-injected hindlimbs ( Figure 5B and 5C), suggesting that arteriogenesis was also induced. Importantly, Etv2 lentivirusinjected muscle were protected from necrotic damage caused by ischemia ( Figure 5D , top). Fibrosis, measured by Masson trichrome staining, was also markedly attenuated in these animals, compared with controls ( Figure 5D , bottom and 5D′).
Etv2-Mediated Activation of Angiogenic Program in Vascular Regeneration
To understand mechanisms by which ETV2 regulates vascular regeneration, we first examined changes in cell population in ischemic hindlimbs. Notably, fewer endothelial cells were present in the ischemic hindlimbs shortly after the injury (4 days later), probably reflecting apoptotic response of endothelial cells to ischemia. 35 In contrast, there was a significant increase in CD45 + blood cells at this time in the injured hindlimbs, presumably indicating an elevated inflammatory response to injury ( Figure 6A and 6B). To further understand molecular events occurring after injury, we examined gene expression profiles in the mouse hindlimb tissues collected 7 days after the ischemic injury. We chose this time point because vessel remodeling had initiated and inflammation was beginning to subside at this time. 35, 36 Angiogenesis polymerase chain reaction array analysis showed that expression of the inflammation-related cytokines, including Il6, Il1β, Cxcl2, and Cxcl5, was highly upregulated at this time point in the injured tissues ( Figure 6C ; Table I in the online-only Data Supplement). However, angiogenesis-related genes were generally downregulated. In particular, Vegfs and their receptors, Flk1 and Flt1 expression levels were lower in the injured tissues, which could be partly because of decreased numbers of endothelial cells in the injured tissue. To investigate molecular changes induced by ETV2, we additionally performed an angiogenesis polymerase chain reaction array using RNA obtained from hindlimb tissues that received Etv2 and compared with that of the controls (collected 7 days after injury; Figure 6D ; Table II in the online-only Data Supplement). On Etv2 lentivirus injection, inflammatory and chemokine gene expression was downregulated. Conversely, a majority of the angiogenic genes that were downregulated in the ischemic tissue became upregulated by lentiviral Etv2. Notably, Vegfs, Flk1, and Flt1 expression was increased. Western blot analysis confirmed increased CD31, smooth muscle α-ACTIN, FLK1, and VEGF protein levels without significant changes in fibroblast growth factor 2 (FGF2) production in Etv2-injected hindlimbs ( Figure 6E ). Collectively, these results suggest that Etv2 expression in ischemic hindlimbs leads to an augmented 
ETV2 Regulates VEGF Response in Vascular Regeneration
Because the VEGF-FLK1 pathway was highly upregulated by lentiviral Etv2 delivery during vessel regeneration, we examined whether the FLK1 pathway, the key downstream target of ETV2 in embryonic vascular development, [12] [13] [14] could also be a target of ETV2 in neovascularization in the adult. Notably, Flk1 expression levels in endothelial cells isolated from Tie2Cre; Etv2 CKO ischemic hindlimbs were much lower, compared with controls ( Figure 7A ). To determine if endothelial cells lacking Etv2 show a diminished response to VEGF as a result of blunted Flk1 upregulation, we performed a choroidal explant culture assay, an in vitro quantitative measurement of angiogenesis.
37 Tie2-Cre; Etv2 CKO choroidal explants + cells from adductor muscle. Cells were sorted from control and Tie2-Cre; Etv2 CKO mice 7 days after ishcemic injury. Sorted cells from 4 mice/group were combined and used for gene expression analysis. C, Representative images showing physiological status and blood perfusion measured by Laser Doppler Perfusion Image (LDPI) of control and Tie2-Cre; Etv2 CKO ischemic hindlimbs. D, Blood perfusion ratio of ischemic limbs of control and Tie2-Cre; Etv2 CKO mice imaged on days 0, 3, 7, 14, and 21 after ischemic injury is shown; n=5/group, **P<0.01. E, Representative images of immunohistochemistry. Adductor muscle from control and Tie2-Cre; Etv2 CKO mice were harvested 21 days after injury and subjected to immunohistochemistry using anti-CD31 (platelet/endothelial cell adhesion molecule-1 [PECAM1]) or CD144 (VECADHERIN) antibody. 4′,6-Diamidino-2-phenylindole (DAPI; blue) for nuclear staining, Scale bars, 100 µm. F, Quantification of CD31 (PECAM1) or CD144(VECADHERIN)-positive vessel density in the ischemic region is shown. n=5/group, *P<0.05. G, Representative images of physiological status and blood perfusion measured by LDPI of control and VECadherin-Cre; Etv2 CKO ischemic hindlimbs. H, Blood perfusion ratio of ischemic limbs of control and VECadherin-Cre; Etv2 CKO mice imaged on days 0, 3, 7, 14, and 21 after ischemic injury is shown; n=5/group, *P<0.05. I, Representative photographs of immunohistochemistry are shown. Adductor muscle from control and VECadherin-Cre; Etv2 CKO mice were harvested 21 days after injury and subjected to immunohistochemistry with anti-CD31(PECAM1) antibody. DAPI (blue) for nuclear staining, Scale bars, 100 µm. J, Quantification of CD31(PECAM1)-positive vessel density in the ischemic region is shown; n=5/group, *P<0.05. Error bars indicate SDs.
showed impaired endothelial sprouting in the presence of VEGF compared with controls ( Figure 7B , left, column 1 versus 3; Figure VIII in the online-only Data Supplement). Although VEGF-mediated sprouting from control explants was suppressed by the VEGF inhibitor bevacizumab treatment 38 ( Figure 7B , left, columns 1 versus 2), the Tie2-Cre; Etv2 CKO explants were unaffected by Bevacizumab ( Figure 7B , left, columns 3 versus 4), suggesting that impaired sprouting in Etv2-deficient endothelial cells is partly because of a compromised VEGF-FLK1 response. Notably, Tie2-Cre; Etv2 CKO and control choroidal explants showed a similar response to FGF2 ( Figure 7B , right, columns 1 versus 3). In addition, bevacizumab did not affect FGF2 responsive vascular sprouting ( Figure 7B , right, columns 1 versus 2, columns 3 versus 4).
To further validate the ETV2-FLK1 pathway in vascular regeneration, we used in vitro differentiated embryonic stem cells (embryoid bodies [EBs]), which exhibit robust endothelial differentiation and sprouting angiogenesis on collagen I matrix or matrigel. [39] [40] [41] Specifically, doxycyclin inducible Etv2 EBs 12 were subjected to sprouting angiogenesis on a solidified collagen I matrix in the presence of VEGF, doxycline or VEGF and doxycline. As previously reported, EB sprouting angiogenesis was induced by VEGF. 39, 41 Notably, If indeed the FLK1 pathway functions downstream of ETV2 in vascular regeneration, it was expected that Flk1 expression would rescue the neovascularization defects observed in Tie2-Cre; Etv2 CKO mice. To test this model, Tie2-Cre; Etv2 CKO mice were subjected to hindlimb ischemic injury followed by lentiviral Flk1 delivery into the adductor muscle. Although control lentiviral injection had no effect on limb perfusion recovery, lentiviral Flk1 injection into Tie2-Cre; Etv2 CKO ischemic hindlimbs restored the impaired blood perfusion (Figure 7E and 7F ; Figure X in the online-only Data Supplement). Moreover, vessel density of the CKO hindlimbs was augmented by Flk1 lentivirus injection, compared with controls ( Figure 7G and 7H) .
To further validate that ETV2-mediated vascular regeneration is facilitated through activating the FLK1 pathway, we subjected wild-type, Etv2 +/− and Flk1 +/− single heterozygous mice and Etv2
+/− double heterozygous mice to hindlimb ischemic injury ( Figure 7I ). Etv2 +/− or Flk1 +/− single heterozygous mice showed a trend (not statistically significant) toward impaired recovery in limb perfusion compared with wild-type controls, suggesting the potential of a haploinsufficient role for Etv2 or Flk1 in vascular regeneration. Importantly, Etv2
+/− double heterozygous mice showed significantly (P<0.05) worse blood perfusion recovery compared with either single heterozygous mouse. These data support a role for Etv2 and Flk1 within a common genetic pathway in vessel regeneration.
Discussion
Angiogenesis is fundamental for successful tissue repair and regeneration. It is widely accepted that genetic programs regulating developmental angiogenesis also drive postnatal angiogenesis. For example, VEGF and FLK1 have been extensively studied in the context of embryonic vessel development, vascular regeneration, and pathological angiogenesis. Notably, Vegfa or Flk1 deficiency leads to embryonic lethality because of defects in vascular and hematopoietic formation. [42] [43] [44] Importantly, neovascularization in ischemic limbs or myocardial ischemia can be enhanced by VEGF administration, suggesting that a proangiogenic approach may be beneficial for ischemic vascular occlusion. 45 Moreover, VEGF targeted therapy is commonly used to correct pathological angiogenesis, such as in age-related macular degeneration and tumors. Tissue injuries or tumors create a hypoxic environment and hypoxia is a key upstream inducer of Vegf activation, which may explain how the VEGF pathway can be activated in various pathological conditions. However, the upstream events leading to FLK1 activation or inhibition in endothelial cells under pathophysiological conditions have not been well characterized.
ETV2 function is indispensable for vessel development because Etv2 deficiency, similar to Vegf or Flk1 deficiency, leads to an absolute block in blood and vessel formation and embryonic lethality. However, Etv2 deletion using Tie2-Cre, VECadherin-Cre, or Vav-Cre does not affect normal embryonic development, indicating that Etv2 is only transiently required during vessel and blood specification. Consistently, Etv2 expression becomes silent once the circulatory system is established and is not detectable beyond E11.5, especially in endothelial cells. [10] [11] [12] These studies raise an important question as to whether Etv2 is dispensable in postnatal life. Because mice lacking endothelial Etv2 displayed seemingly normal homeostatic vessel maintenance, we determined in this study whether ETV2 could be involved in injury response. A major unexpected finding of this study is that although ETV2 is not required for steady-state vessel maintenance, Etv2 is necessary for efficient vessel regeneration in response to injury. There was noticeable upregulation of Etv2 in endothelial cells isolated from ischemic tissues. Endothelial Etv2 deficiency led to a poor vascular regeneration capacity. Thus, our findings are consistent with the notion that embryonic signaling either through reactivation or through dysregulation can become an important cause in the pathophysiological events in adults. [46] [47] [48] + cells from adductor muscle of control and Tie2-Cre; Etv2 conditional knockout (CKO) mice. Cells were sorted 7 days after ishcemic injury. Sorted cells from 4 mice/group were combined and used for gene expression analysis. B, Angiogenic sprouting in Tie2-Cre; Etv2 CKO choroidal explants. Choroidal explants of the controls and Tie2-Cre; Etv2 CKO mice were subjected to angiogenic sprouting assay and the mean sprout length was measured 9 days later; n=4/group, ***P<0.001. C, Representative CD31 staining of embryoid body (EB) sprouts are shown. 4′,6-Diamidino-2-phenylindole (DAPI; blue) staining for nucleus is shown. Scale bar, 100 µm. D, Quantification of the number of sprouts per EB (left) and the total sprout length (right) is shown; n=5/group, *P<0.05. Error bars indicate SDs. E, Representative images of blood perfusion of Tie2-Cre; Etv2 CKO mice injected with lentiviral Venus or Flk1. Images were obtained on days 0 and 21 after ischemic injury. F, Blood perfusion ratio of ischemic hindlimbs measured by Laser Doppler Perfusion Image (LDPI) in Tie2-Cre; Etv2 CKO injected with lentiviral Venus or Flk1 is shown; n=4/group, *P<0.05. G, Representative images of CD31 immunohistochemistry. Adductor muscle from Tie2-Cre; Etv2 CKO and Tie2-Cre; Etv2 CKO mice injected with lentiviral Flk1 were harvested 21 days after injury and subjected to immunohistochemistry with anti-CD31 (platelet/endothelial cell adhesion molecule-1 [PECAM1]) antibody. DAPI (blue) for nuclear staining, Scale bars, 100 µm; H, Quantification of CD31(PECAM1)-positive vessel density in the ischemic region; n=4/group, *P<0.05. I, A genetic interation between ETV2 and FLK in ischemia-induced angiogenesis. Wild-type (n=9), Etv2 +/− (n=16), Flk1 +/− (n=14) and Etv2
+/− (n=11) mice were subjected to hindlimb ischemia and blood perfusion ratio of the ischemic limbs was measured on days 0, 3, 7, 14, and 21 after the injury using LDPI. *P<0.05, wt, Etv2 relationship between ETV2 and FLK1 in vascular regeneration. Although ETV2 functions upstream of Flk1 in development and in injury-mediated response as we showed in this study, several papers reported that ETV2 could be induced by VEGF. 11, 49 Notably, VEGF is readily induced in hypoxic conditions. It has recently been suggested that there is a positive feedback mechanism between ETV2 and FLK1 signaling in embryogenesis.
14 Thus, although injury signals that can lead to Etv2 reactivation remain to be elucidated, it is possible that ETV2-FLK1 feedback mechanism might amplify the VEGF response in vascular regeneration.
A single lentiviral Etv2 injection was sufficient to protect mice from limb loss and enhanced blood perfusion in ischemic hindlimbs. Furthermore, Etv2 lentivirus-injected muscle was protected from necrotic damage caused by ischemic injury. One simple explanation for the potent function of ETV2 in this process would be that endothelial cells infected with ETV2 proliferate and activate angiogenic program and thus generate more blood vessels, leading to tissue protection. Indeed, we found that endothelial cells were readily infected by lentiviral Etv2 in the injured tissues. Because ETV2 delivery can also induce arteriogenesis, it might be possible that endothelial ETV2 upregulates the expression of paracrine factors for smooth muscle cell recruitment and proliferation. Intriguingly, recent studies show that ETV2 can directly reprogram somatic cells into functional endothelial cells in vitro. [50] [51] [52] In addition, ectopic etv2 expression in zebrafish was able to convert skeletal muscle cells into endothelial cells. 53 Thus, it is also possible that reprogrammed endothelial cells in the ischemic hindlimbs from other cell types such as skeletal muscle cells, fibroblasts, or hematopoietic cells, if any, could also have contributed to the observed protected phenomenon. In agreement with this, we found that hematopoietic cells and presumably skeletal muscles were also infected with lentiviral Etv2 in ischemic hindlimbs. Future studies are warranted whether Etv2 expression could indeed cause in vivo conversion of nonendothelial cells into endothelial cells and if so, then the magnitude of contribution of such in vivo reprogrammed endothelial cells to vascular regeneration. Intriguingly, Etv2 expression was no longer detected once the vascular regeneration was completed in the mouse hindlimb ischemia model. A transient, but not persistent, upregulation of Etv2 in the initial stages of vascular regeneration might, therefore, be critical. Reminiscent to the transient Etv2 expression pattern during embryogenesis, [10] [11] [12] there might be a strong pressure to keep this gene off in established vasculature. Indeed, sustained expression of Etv2 in Tie2 + cells leads to abnormal vessel development as manifested by dilated yolk sac vessels. 54 Collectively, our findings suggest that Etv2 delivery into injured tissues could be used for therapeutic purpose for conditions requiring vessel regeneration.
A recent study has demonstrated that FGF2, probably through FGFR1/2, can activate Flk1 expression via ERK-ETS. 55 However, we found that Tie2-Cre; Etv2CKO and control choroidal explants showed similar vascular sprouting in response to FGF2, suggesting that FGF2 could regulate Flk1 expression by ETV2-independent manner. In the absence of ETV2, other ETS factors such as ETS1 could function downstream of FGF2 in regulating Flk1 expression. In addition, the observed discrepancy might be because of (1) FGF2 treatment to choroidal explants versus adenoviral delivery of FGFR1 DN to HUVECs or (2) different genetic models; Tie2-Cre; Etv2 CKO versus FGFR1 DN transgenic mice. We propose that ETV2 is critical for regulating VEGF/FLK1 signaling, but dispensable for FGF2 signaling in neoangiogenesis. Combined FGFRs and ETV2 inactivation in endothelial cells is warranted in the future to further understand the interplay between FGF and VEGF/FLK1 signaling with regard to ETV2 in vascular regeneration.
In conclusion, we demonstrated that endothelial Etv2 is critical for vessel regeneration and tissue repair after injury. In addition, ETV2 has potent efficacy in therapeutic angiogenesis, providing a novel research platform for vascular regeneration therapies. Current therapeutic angiogenic targets such as VEGF have presented severe limitations in specifically targeting vessels undergoing neoangiogenesis, as they are also required for vessel homeostasis. In contrast, Etv2 is activated in endothelial cells on injury, thus aiming the ETV2 pathway could provide unique opportunity for specifically targeting the activated endothelial cells, while sparing homeostatic vessel integrity. 
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